Suvankar Pal

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9634961/publications.pdf

Version: 2024-02-01

53	1,976	361413	254184
papers	citations	20	43
		h-index	g-index

57	57	57	2910
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A systematic review of non-motor symptom evaluation in clinical trials for amyotrophic lateral sclerosis. Journal of Neurology, 2022, 269, 411-426.	3.6	21
2	Validation of Revised International Creutzfeldt-Jakob Disease Surveillance Network Diagnostic Criteria for Sporadic Creutzfeldt-Jakob Disease. JAMA Network Open, 2022, 5, e2146319.	5.9	28
3	070â€... A pilot study assessing choroidal thickness in frontotemporal dementia and motor neuron disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A122.2-A122.	1.9	1
4	Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease. BMJ Open, 2022, 12, e064173.	1.9	10
5	A systematic review of neuropsychiatric and cognitive assessments used in clinical trials for amyotrophic lateral sclerosis. Journal of Neurology, 2021, 268, 4510-4521.	3.6	22
6	The immediate impact of the COVID-19 pandemic on motor neuron disease services and mortality in Scotland. Journal of Neurology, 2021, 268, 2038-2040.	3.6	6
7	Application of telehealth for comprehensive Creutzfeldt-Jakob disease surveillance in the United Kingdom. Journal of the Neurological Sciences, 2021, 420, 117221.	0.6	7
8	40 Years of CSF Toxicity Studies in ALS: What Have We Learnt About ALS Pathophysiology?. Frontiers in Molecular Neuroscience, 2021, 14, 647895.	2.9	10
9	Prospective observational cohort study of factors influencing trial participation in people with motor neuron disease (FIT-participation-MND): a protocol. BMJ Open, 2021, 11, e044996.	1.9	6
10	The prevalence of multimorbidity and its impact on survival in people with motor neuron disease. European Journal of Neurology, 2021, 28, 2756-2765.	3.3	2
11	Non-white cases of sporadic Creutzfeldt-Jakob disease: A 28Âyear review of United Kingdom National Surveillance Data. Journal of the Neurological Sciences, 2021, 424, 117416.	0.6	0
12	The importance of ongoing international surveillance for Creutzfeldtâ€“Jakob disease. Nature Reviews Neurology, 2021, 17, 362-379.	10.1	69
13	Validation of The Edinburgh cognitive and behavioural ALS screen (ECAS) in behavioural variant frontotemporal dementia and Alzheimerâ€™s disease. International Journal of Geriatric Psychiatry, 2021, 36, 1576-1587.	2.7	5
14	Phenotypic diversity of genetic Creutzfeldtâ€“Jakob disease: a histo-molecular-based classification. Acta Neuropathologica, 2021, 142, 707-728.	7.7	24
15	Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective. Brain Communications, 2021, 3, fcab242.	3.3	32
16	Trials for neurodegenerative diseases: time to innovate. Lancet Neurology, The, 2021, 20, 984.	10.2	9
17	Impact of the COVIDâ€19 pandemic on Creutzfeldtâ€“Jakob disease surveillance and patient care in the United Kingdom. European Journal of Neurology, 2021, , .	3.3	4
18	The brief Dimensional Apathy Scale: A short clinical assessment of apathy. Clinical Neuropsychologist, 2020, 34, 423-435.	2.3	22

#	Article	IF	Citations
19	An epidemiological profile of dysarthria incidence and assistive technology use in the living population of people with MND in Scotland. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 116-122.	1.7	6
20	Cerebrospinal fluid cytotoxicity in amyotrophic lateral sclerosis: a systematic review of in vitro studies. Brain Communications, 2020, 2, fcaa121.	3.3	10
21	Understanding the risk of incidental findings: A qualitative study of people with cognitive symptoms. Journal of the Neurological Sciences, 2020, 419, 117203.	0.6	0
22	Excellent reliability of the ALSFRS-R administered via videoconferencing: A study of people with motor neuron disease in Scotland. Journal of the Neurological Sciences, 2020, 416, 116991.	0.6	4
23	Reliability and validity of the brief dimensional apathy scale. Archives of Clinical Neuropsychology, 2020, 35, 539-544.	0.5	13
24	Relationship between neuropsychiatric disorders and cognitive and behavioural change in MND. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 245-253.	1.9	15
25	Riluzole prescribing, uptake and treatment discontinuation in people with amyotrophic lateral sclerosis in Scotland. Journal of Neurology, 2020, 267, 2459-2461.	3.6	4
26	Executive, language and fluency dysfunction are markers of localised TDP-43 cerebral pathology in non-demented ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 149-157.	1.9	54
27	The Prevalence and Management of Saliva Problems in Motor Neuron Disease: A 4-Year Analysis of the Scottish Motor Neuron Disease Register. Neurodegenerative Diseases, 2020, 20, 147-152.	1.4	5
28	The assessment of visually guided reaching in prodromal Alzheimerâ€™s disease. Journal of Vision, 2020, 20, 1059.	0.3	0
29	Screening for cognitive impairment among patients with neuromyelitis optica using touchscreen cognitive testing in routine clinical care. Journal of Neurology, 2019, 266, 2571-2572.	3.6	2
30	Surveillance for variant CJD: should more children with neurodegenerative diseases have autopsies?. Archives of Disease in Childhood, 2019, 104, 360-365.	1.9	7
31	Clinical audit research and evaluation of motor neuron disease (CARE-MND): a national electronic platform for prospective, longitudinal monitoring of MND in Scotland. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 242-250.	1.7	19
32	Changing epidemiology of motor neurone disease in Scotland. Journal of Neurology, 2019, 266, 817-825.	3.6	40
33	Incidental Findings Identified on Head MRI for Investigation of Cognitive Impairment: A Retrospective Review. Dementia and Geriatric Cognitive Disorders, 2019, 48, 123-130.	1.5	8
34	ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology, 2018, 91, e1370-e1380.	1.1	170
35	Clinicopathological case: progressive somnolence and dementia in an accountant: when the shine rubs off the gold standard. Practical Neurology, 2018, 18, 505-512.	1.1	0
36	Investigating Domain-Specific Cognitive Impairment Among Patients With Multiple Sclerosis Using Touchscreen Cognitive Testing in Routine Clinical Care. Frontiers in Neurology, 2018, 9, 331.	2.4	17

#	Article	IF	Citations
37	TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis. BMC Neurology, 2018, 18, 90.	1.8	63
38	Genetic epidemiology of motor neuron disease-associated variants in the Scottish population. Neurobiology of Aging, 2017, 51, 178.e11-178.e20.	3.1	37
39	Bilateral lower limb weakness in acute severe ulcerative colitis. Lancet, The, 2016, 388, 101-102.	13.7	7
40	Improved PCR based methods for detecting C9orf72 hexanucleotide repeat expansions. Molecular and Cellular Probes, 2016, 30, 218-224.	2.1	42
41	A systematic review and metaâ€analysis of ¹⁸Fâ€labeled amyloid imaging in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 5-13.	2.4	59
42	P2-190: Detecting profiles of cognitive performance in dementia syndromes and parkinson's disease using brief computerized cognitive tests. , 2015, 11, P565-P565.		0
43	Functional (Psychogenic) Cognitive Disorders: A Perspective from the Neurology Clinic. Journal of Alzheimer's Disease, 2015, 48, S5-S17.	2.6	83
44	Influence of Intracerebral Hemorrhage Location on Incidence, Characteristics, and Outcome. Stroke, 2015, 46, 361-368.	2.0	142
45	A systematic review and metaâ€analysis of retinal nerve fiber layer change in dementia, using optical coherence tomography. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 136-143.	2.4	133
46	Non-Motor Symptoms Profile and Burden in Drug NaÃ¯ve Versus Long-Term Parkinson's Disease Patients. Journal of Parkinson's Disease, 2014, 4, 541-547.	2.8	41
47	The diagnostic utility of EEG in early-onset dementia: a systematic review of the literature with narrative analysis. Journal of Neural Transmission, 2014, 121, 59-69.	2.8	53
48	Systematic review of the diagnostic utility of SPECT imaging in dementia. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 539-552.	3.2	56
49	31st Advanced Clinical Neurology Course, Edinburgh 2009: progressive cognitive impairment, behavioural change and upper motor neuron signs in a 57-year-old woman. Practical Neurology, 2011, 11, 71-80.	1.1	1
50	A challenging case of double vision and altered facial sensation. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 539-540.	1.9	0
51	Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurology, The, 2009, 8, 334-344.	10.2	226
52	Progressive unsteadiness in a 68-year-old man with longstanding abdominal pain and altered bowel habit. Practical Neurology, 2009, 9, 210-220.	1.1	4
53	Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet, The, 2006, 368, 2061-2067.	13.7	374